To determine whether routine antibiograms (summaries reporting resistance of all tested isolates) reflect resistance rates among pathogens associated with hospital-acquired infections, we compared data collected from 2 different surveillance components in the same 166 intensive care units (ICUs). ICUs reported data during the same months to both the infection-based surveillance and the laboratory-based surveillance. Paired comparisons of the percentage of isolates resistant were made between systems within each ICU. No significant differences existed ( ) between the percentage of isolates resistant from the infection-based system and laboratory-based system P 1 .05 for all antimicrobial-resistant organisms studied, except methicillin resistance in Staphylococcus species. The mean difference in percentage resistance was higher from the infection-based system than the laboratory-based system for S. aureus (mean difference, +8%, ) and coagulase-negative staphylococci (mean difference, P ! .001 +9%, ). Overall, hospital antibiograms reflected susceptibility patterns among isolates associated with P ! .001 hospital-acquired infections. Hospital antibiograms may underestimate the relative frequency of methicillin resistance among Staphylococcus species when associated with hospital-acquired infections.
infections and community infections to best aid in empiric therapy decisions. Such reports would be difficult to generate by many clinical microbiology laboratories. Validating the clinical relevance of "all-isolate" summaries for health care-acquired infections would provide support for the current widespread practice of using a single summary report in most hospitals.
To augment surveillance for antimicrobial resistance at hospitals in the United States, the Hospital Infections Program at Centers for Disease Control and Prevention (CDC), in collaboration with the Rollins School of Public Health of Emory University, began Project ICARE (Intensive Care Antimicrobial Resistance Epidemiology) in 1996 at a subset of hospitals participating in CDC's National Nosocomial Infections Surveillance (NNIS) system. Project ICARE hospitals reported data on all strains of selected bacteria tested in the clinical microbiology laboratory. These data allowed for determination of prevalence rates of resistance similar to the routine hospital cumulative antibiogram. The cumulative antibiogram or cumulative susceptibility test data report is the percentage of isolates of a given species tested in a given institution, or specific areas of the institution, that are susceptible or resistant to each of the antimicrobial agents routinely tested. We used data gathered from hospitals participating in our study to study differences in the prevalence of resistance in participating intensive care units (ICUs) among bacteria reported through laboratorybased surveillance (as reported through Project ICARE) to the prevalence of resistance among isolates associated with hospitalacquired infections reported through infection-based surveillance (pathogens reported through the NNIS-ICU component). Validation of the clinical relevance of the routine hospital antibiogram would increase the confidence level among clinicians that laboratory-based data can guide empiric therapy for patients with hospital-acquired infections.
METHODS
Surveillance data and sites. Hospitals that participate in the ICU surveillance component of the NNIS-ICU system were invited to participate in Project ICARE (NNIS-ICARE), and 61 hospitals representing 171 ICUs submitted data to Project ICARE and the ICU component of the NNIS system during the study period January 1996-April 2000. The surveillance methodology and definitions of the NNIS system [4, 5] and Project ICARE [6] have been described elsewhere.
Infection-based reports. Participating hospitals reported monthly hospital-acquired infection data from at least one ICU to NNIS-ICU. The NNIS-ICU data include information on all hospital-acquired infections (infections occurring at any site) detected in patients during the month in which active surveillance occurred in the ICU (figure 1). The susceptibility interpretation (susceptible, intermediate, resistant) for drugs tested against each pathogen associated with the hospital-acquired infection is reported according to NCCLS breakpoint definitions [7] [8] [9] . This allows for determining the cumulative susceptibility report, or antibiogram, of all pathogens associated with hospital-acquired infections during that month (hospitalacquired infection-based cumulative antibiogram). As participants in the NNIS system, hospital personnel had previously categorized each ICU at their hospital by the types of patients served: coronary, medical, general surgical, cardiothoracic, combined medical-surgical (units where !80% of patients can be classified into a single unit type), neurosurgical, respiratory, trauma, or burn. A proficiency testing of Project ICARE clinical microbiology laboratories determined that despite different methodologies, testing produced accurate results to 6 challenge organisms [10] .
Laboratory-based reports. As part of NNIS-ICARE, hospitals also reported susceptibility data on select organisms from clinical specimens (e.g., blood, urine, sputum, and wound) obtained from patients in these same ICUs, whether associated with hospital-acquired or community-acquired infection or colonization (figure 1). Duplicate isolates were excluded; these were defined as isolates of the same organism with the same antimicrobial resistance pattern recovered from the same patient, regardless of the site of isolation, during the same calendar month. This allowed for determining the cumulative susceptibility report, or antibiogram, of all organisms processed from clinical specimens submitted to the clinical microbiology laboratory (laboratory-based cumulative antibiogram).
Data analysis. Data were analyzed by SAS version 6.12 software (SAS). For each ICU, only months in which data were reported to both NNIS-ICU and NNIS-ICARE were selected for analysis (eligible unit-months; figure 1 ). For all of the eligible unit-months, pooled data (aggregate data combining all eligible unit-months for each ICU) about each organism were compared between the laboratory-based and infection-based reporting systems within each ICU. The testing rates (number of isolates tested against a specified antimicrobial per month) and prevalence rates of resistance (percentage of isolates tested that were resistant) were calculated for each reporting system. Prevalence rates of resistance were calculated only if у10 isolates were tested to the specified antimicrobial in the pooled data, and included rates for methicillin-resistant Staphylococcus aureus (MRSA); methicillin-resistant coagulase-negative staphylococci; vancomycin-resistant Enterococcus species, ciprofloxacin-resistant or ofloxacin-resistant Escherichia coli; ceftazidime-resistant, cefotaxime-resistant, or ceftriaxone (third-generation cephalosporin)-resistant E. coli; third-generation cephalosporin-resistant Klebsiella pneumoniae; third-generation cephalosporin-resistant Enterobacter species; piperacillin-resistant Pseudomonas aeruginosa; ceftazidime-resistant P. aeruginosa; imipenem-resistant P. aeruginosa, and ciprofloxacin-resistant or ofloxacin-resistant P. aeruginosa.
Further analysis included pairwise comparisons of the average number of isolates tested per month and the average difference in resistance rate (infection-based rate minus laboratory-based rate). Pairwise comparisons were performed to measure the difference between reporting systems (laboratory based vs. infection based) within each ICU. A x 2 test was performed to test the homogeneity of the differences among all ICUs. These comparisons were aggregated to determine statistical significance. If the differences were homogeneous, a weighted mean was calculated and tested against zero by means of a Z test to determine a P value. In case of nonhomogeneity, the average difference was also tested against zero by means of a Z test. Additionally, to test for absence of mean effect both. Wilcoxon signed rank and paired t tests were also used to confirm the above analyses (data not shown).
RESULTS

Sites.
During the study period, 61 hospitals followed the NNIS-ICARE surveillance protocol and reported a median of 12 months of data from all isolates tested in 166 ICUs, for a total of 2669 ICU-months of laboratory-based susceptibility data. During the study period, these hospitals reported 12,398 hospital-acquired infections from the same ICUs, providing a total of 2080 ICU-months of infection-based susceptibility data during months overlapping with the laboratory-based susceptibility data (for some months, no infections were reported). Hospitals were in 26 states (4 New England, 15 mid-Atlantic, 19 south Atlantic, 13 east-central, 6 west-central, and 4 Pacific hospitals) and had a median of 385 hospital beds (range, 147-1206 beds); 30 (50%) reported a major affiliation with a teaching institution (major teaching centers), and 6 (10%) were Veterans Affairs Medical Centers. The ICUs included 45 medical-surgical ICUs, 28 medical ICUs, 26 general surgical ICUs, 22 CCUs, 18 cardiothoracic ICUs, 12 pediatric ICUs, 9 neurosurgical ICUs, 3 trauma ICUs, 2 burn ICUs, and 1 respiratory ICU.
Frequency of organism testing. For the 11 antimicrobialresistant organisms evaluated, the ICU-specific average number of organisms tested for susceptibility varied by organism, antimicrobial agent tested, and reporting system. In the laboratorybased system, the testing rate for S. aureus and coagulase-negative staphylococci tested to methicillin group agents was highest (median values of 3.1 and 3.3 organisms tested per month, respectively), whereas Enterobacter species tested for third-generation cephalosporin susceptibility was lowest (median value of 1.4 organisms per month). In contrast, the average testing rate by the infection-based system (organisms associated with a hospital-acquired infection) was consistently р1 per month. Therefore, the testing rate of the laboratory-based system was ∼4-fold higher than for the infection-based reporting (table 1) .
Prevalence of resistance to antimicrobial agents. The prevalence of resistance to antimicrobial agents from the study hospitals reporting to the infection-based system (table 2) was similar to that previously reported from the all NNIS hospitals reporting data from ICU patients (http://www.cdc.gov/ncidod/ hip/surveill/nnis.htm) [11] . For the 11 antimicrobial-resistant organisms evaluated, the number of ICUs testing у10 organisms was consistently higher when we used data from the laboratory-based reporting system (median value, 110, range, 96-132 ICUs) than the infection-based system (median value, 26, range, 10-44 ICUs). Therefore, comparisons between the 2 reporting systems is limited to those ICUs that reported susceptibility results on a sufficient numbers of organisms by the infection-based system. The prevalence rates of resistance to antimicrobial agents among all ICUs were usually higher among isolates reported to the infection-based system than among isolates reported to the laboratory-based system (table 2). However, these differences were rarely statistically significant when we used the pairwise comparisons, which takes into account the differences observed within each ICU and the consistency with which these differences were observed. There were 2 notable exceptions. By use of the pairwise comparisons, infection-based prevalence of resistance was significantly higher than laboratory-based prevalence for MRSA (average difference, ϩ7.9%;
) and P ! .001 methicillin-resistant coagulase-negative staphylococci (mean difference, ϩ8.7%;
; table 2). Similar comparisons for P ! .001 the other organisms evaluated identified no additional significant differences. Similar analysis comparing the percentage of isolates susceptible to the antimicrobial revealed similar results.
It is of note that the mean difference in the prevalence of vancomycin-susceptible enterococci between the 2 systems was 11%, although this difference still did not reach statistical significance.
DISCUSSION
Aggregating cumulative susceptibility data is a common practice among clinical microbiology laboratories, but the best methodology to analyze and present these data has not been determined. The most common use of the hospital antibiograms data is probably for assisting clinicians with empiric therapy for suspected infections [2] . Our study suggests cumulative susceptibility data (laboratory-based reporting) that clinicians use to guide empiric treatment of hospital-acquired infections usually will be representative of the organisms frequently encountered among hospital-acquired infections. Our study evaluated select patterns of resistance to antimicrobial agents among the organisms most frequently associated with hospital-acquired infections and compared the resistance rates reported to a laboratory-based monitoring system (NNIS-ICARE) to rates reported to an infection-based monitoring system (NNIS-ICU). With 2 exceptions, the resistance rates among isolates associated with only hospital-acquired infections were similar to rates among isolates associated with infection (both community and hospital acquired), colonization, and contaminants.
The 2 organisms associated with significantly higher rates of NOTE. Included are data from ICUs that reported sufficient data (у10 isolates) to both laboratory-based and infectionbased reporting systems and the average difference in prevalence by reporting system, National Nosocomial Infections Surveillance System, January 1996-April 2000. IBRS, infection-based reporting system; LBRS, laboratory-based reporting system; %R, prevalence of resistance.
a Weighted mean difference for all organisms except S. aureus and coagulase-negative staphylococci (arithmetic mean resistance among isolates reported to the infection-based system compared with the laboratory-based system were MRSA and methicillin-resistant coagulase-negative staphylococci. Although several other organisms tended to be associated with higher resistance rates in the infection-based system, these differences were not statistically significant. We would expect that resistance to antimicrobial agents is more frequently encountered among organisms associated with hospital-acquired infections compared with community-infections for several reasons. First, previous analysis of data from Project ICARE demonstrated that, with a few exceptions (i.e, Streptococcus pneumoniae), organisms with onset of disease in the community (from the outpatient or emergency department setting) are less likely to be resistant to antimicrobial agents than are those encountered in the inpatient setting [6] . Second, patients with longer hospital stays are at increased risk to become infected with antimicrobial-resistant pathogens, and these isolates would be more represented in a infection-based system (i.e., nosocomial infection) than the laboratory-based system [3, [12] [13] [14] . Third, there would be potential for reporting bias if infection control practitioners were more likely to report hospital-acquired infections when they were associated with an antimicrobial-resistant pathogen, although this seems unlikely. Some of these hypotheses may explain the significantly higher resistance rates observed in data from infection-based reporting compared with that from laboratory-based reporting among MRSA and methicillin-resistant coagulase-negative staphylococci. However, the impact of these factors does not appear strong enough to consistently create differences in measured resistance prevalence of any magnitude worthy of clinical importance. If the sample of data were larger, we might have identified more significant differences in the reporting systems. However, the relative differences in resistance prevalence observed were small (!10%) and unlikely to have any clinical impact, even if differences were to become statistically significant. We limited our study to ICUs because our surveillance data for hospital-acquired infections were limited to the ICU. Currently, the NNIS system does not receive reports from hospitalwide surveillance, making comparisons to the non-ICU areas impossible. Although this study involved data from only ICU patients, its conclusions may be applicable to hospital-wide data. This is because we evaluated the differences in reported resistance rates within the same ICUs, and we suspect these differences would be of similar magnitude and statistical significance in the non-ICU areas. The major differences between these patient groups in terms of resistance to antimicrobial agents are higher severity of illness and higher rates of resistance to antimicrobial agents [6] . With this lower prevalence of resistance to antimicrobial agents in the non-ICU areas, we may expect any observed differences in the prevalence by reporting system in these hospital areas to be smaller than that observed in our study. A second limitation of our study is the exclusion of many ICUs from some analysis because !10 isolates of a particular organism had been reported to NNIS-ICU during the study period. This may reflect a very low hospital-acquired infection rate overall or a paucity of infections caused by the particular organism under study. Finally, our hypothesis was tested in only select organisms and may not hold true for the less frequently encountered pathogens. Those chosen reflect pathogens thought to have the greatest clinical importance at the inception of Project ICARE. However, comparisons of resistance prevalence among other pathogens of clinical concern (i.e., Acinetobacter species, S. pneumoniae) may not show similar results to our study. For example, others have reported that infections with MRSA that arise outside of the hospital setting (i.e., community-onset MRSA) are frequently associated with MRSA that is susceptible to clindamycin. This is in contrast to the MRSA typically associated with hospital-acquired disease [15] [16] [17] .
These limitations do not detract from the observations that differences between reporting systems were small and not clinically relevant, and mostly insignificant. The findings of comparability of data from the 2 systems have several implications. Analysis of these data supports the aggregation of cumulative susceptibility data from both hospital-acquired infections and other isolates, which may include isolates from communityacquired infections, colonization, or contaminants, into one summary report for use in guiding empiric therapy in hospitalized patients. Clinicians should be aware that the MRSA and methicillin-resistant coagulase-negative staphylococci prevalence rates presented in such summary tables may underrepresent to a small degree their actual prevalence among pathogens associated with hospital-acquired infections. The small magnitude of this difference means that it should rarely affect decisions about drug choice. Therefore, producing one summary report should provide useful relevant data to the clinician and minimize the need for additional efforts to produce more detailed reports on subgroups. However, in some settings, reporting of separate cumulative susceptibility data from ICU areas combined may be useful to clinicians [6] . Likewise, separate reports for specific patient populations (e.g., patients undergoing dialysis or patients with cystic fibrosis) may be helpful as well. Additional studies to identify effective methodologies for providing clinicians with appropriate and valid decision support will be crucial to improving appropriate use of and reducing resistance to antimicrobial agents in health care settings.
